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1. Evolution of Bronchopulmonary Dysplasia
Nearly 50 years ago, Northway and colleagues provided the first clinical, radiologic and
pathologic characterization of the chronic lung disease that follows preterm birth, anointing
this problem as “bronchopulmonary dysplasia (BPD),” due to key pathologic features of that
era (Northway WH et al, 1967). This original report described severe respiratory morbidity
and high mortality in relatively late-gestation preterm infants, largely due to the lack of
surfactant therapy and insufficient neonatal ventilator care at that time. Improved obstetrical
and neonatal care over time has increased survival of even the smallest of immature
newborns over time, yet BPD persists as a major problem, occurring in roughly 10,000
infants per year in the USA alone. Breakthroughs with the use of antenatal steroids,
surfactant therapy, continuous positive airway pressure (CPAP), improved ventilator
technology and strategies, and other interventions, have remarkably improved survival and
outcomes, yet survivors of neonatal intensive care still have substantial late respiratory
morbidity. Preterm birth and its respiratory sequelae have important health care
implications, as infants with BPD require prolonged NICU courses; frequent readmissions
during the first two years after discharge for respiratory infections, asthma, and related
problems; and have persistent lung function abnormalities and exercise intolerance as
adolescents and young adults.(Bland RD and Coalson JJ, 2000; Jobe AH and Bancalari E,
2001; Bancalari E et al, 2001; Jobe AJ, 1999; Charafeddine L et al, 1999; Rojas MA et al,
1995: Laughon M et al, 1999).
The overall incidence of BPD has not declined over the past decade (Laughon M et al,
2010), but the respiratory course and number of infants with severe BPD has clearly
changed with current clinical practice. Infants with chronic lung disease after premature
birth have a different clinical course and pathology than had been traditionally observed in
infants dying with BPD during the pre-surfactant era (Charafeddine L et al, 1999; Rojas et
al, 1995: Laughon M et al, 1999; Smith VC et al, 2005; Hussain E et al, 2000; Coalson JJ,
2000; Jobe AH and Bancalari E, 2001). The classic progressive stages of disease, including
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prominent fibro-proliferative changes, which first characterized BPD are often absent now,
and the disease has changed to being predominantly defined as a disruption of distal lung
growth, referred to as “the new BPD.”(Jobe AH, 1999) In contrast with the past, the “new
BPD” often develops in preterm newborns who may have required minimal or even no
ventilator support and relatively low inspired oxygen concentrations during the early
postnatal days (Charafeddine L et al, 1999; Rojas MA et al, 1995). At autopsy, the lung
histology of infants who die with “the new BPD” displays more uniform and milder injury,
but impaired alveolar and vascular growth remain prominent. (Figure 1A,B) The “new
BPD” is likely the result of disrupted antenatal and postnatal lung growth, leading to
persistent abnormalities of lung architecture and function. Although many of the
implications of how these changes in BPD alter long-term pulmonary outcomes remain
uncertain, this special issue of BDRA brings together a diverse mix of new BPD reviews
and primary data as a window into the remarkable progress and current state of the field.
Despite years of investigation, clinical interventions that have been proven to reduce the risk
for or severity of BPD remain rare. We continue to work towards improving postnatal care
of preterm infants through the application of “best practice” strategies yet clinical practices
and the incidence of new BPD still varies widely between centers (Walsh MA et al, 2007).
Such approaches as less invasive respiratory support, avoidance of excessive hyperoxia,
greater use of lung protective strategies, more aggressive nutrition, the use of vitamin A or
caffeine, may improve outcomes but these strategies are not routinely used across centers.
Recent studies suggest that delivery room practices regarding oxygen use, early institution
of nasal CPAP and surfactant and the avoidance of large tidal volume breaths with bag-mask
ventilation during resuscitation may also be critical determinants of outcomes, but as
discussed by Drs. Deepak and Bancalari, many clinical interventions and their efficacy
remain incompletely studied (Deepak J and Bancalari E, 2014).
2. Changing Epidemiology of BPD
As Northway originally observed, BPD has diverse, multifactorial etiologies, including
hyperoxia, ventilator-induced lung injury, inflammation and infection (Northway WH et al,
1967; Bonikos DS et al, 1976; Crapo JD et al, 1978). In addition to the traditional effects of
postnatal injury, epidemiologic studies over the past decade have further identified critical
perinatal factors that are strongly linked with high risk for BPD. As discussed by Drs. Jensen
and Schmidt, BPD likely begins in utero, as intrauterine growth restriction (IUGR), lack of
antenatal corticosteroids, chorioamnionitis, maternal smoking, placental insufficiency and
other antenatal factors are strongly associated with BPD risk (Jensen E and Schmidt B,
2014; van Marter LJ et al, 1990; Zeitlin J et al, 2010; Bose C et al, 2009; Lee HJ et al, 2010;
Hansen AR et al, 2010; Tang JR et al, 2010; Rozance PJ et al, 2011). Studies in diverse
translational studies using animal models of IUGR, preeclampsia, chorioamnionitis and
other stresses, have provided biologic plausibility that support mechanisms underlying these
epidemiologic findings (van Marter LJ et al, 1990; Zeitlin J et al, 2010; Bose C et al, 2009;
Lee HJ et al, 2010; Hansen AR et al, 2010; Tang JR et al, 2010; Rozance PJ et al, 2011).
Preclinical studies suggest that lung injury due to each of these adverse stimuli is at least
partly mediated through increased oxidative stress that further augments inflammation,
promotes lung injury and impairs growth factor signaling pathways (Davis JM et al, 1993;
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Davis JM et al, 2003). Animal models further suggest that antenatal factors, even
independent of hyperoxia, mechanical ventilation and other postnatal events, are sufficient
to alter lung structure through infancy and into adulthood.
Further studies are needed to determine how different etiologic mechanisms contribute to
the development of new BPD, and such studies may lead to novel interventions for disease-
specific mechanisms underlying new BPD in the clinical setting. Additional insights into
developmental mechanisms underlying normal lung growth and pathogenic mechanisms that
disrupt signaling and cause sustained impairments of lung structure and function are
essential for understanding respiratory outcomes after preterm birth.
3. Developmental Mechanisms of Altered Lung Development in new BPD
BPD results from complex interactions between the degree of prematurity with early
disruption of lung development, the response to acute lung injury, and mechanisms of lung
repair and regeneration. Notably, new BPD primarily occurs in babies born under 29 weeks
gestation, with rates ranging from 40–60%. Preterm birth near the limits of viability at 23–
24 weeks through 28 weeks gestation disrupts the normal progression of lung development
that takes place during the late canalicular, saccular and alveolar stages of normal lung
development. This timing of premature birth clearly precedes the rapid increase in airway
septation and vessel growth that normally accelerates during late gestation. Even relatively
mild increases in oxygen tension may be sufficient to induce inhibitory effects on lung
growth in the setting of extreme prematurity. Factors implicated in aberrant lung
development associated with new BPD include a fragile, structurally and biochemically
immature lung, which enhances susceptibility secondary injury, infection, inflammation,
oxidative stress, mechanical injury associated with positive pressure respiratory support,
apnea and inadequate nutrition. Supportive evidence suggests that genetic and epigenetic
factors modulate the severity to these insults, and that individual responses are further
altered by distinct causal factors that dominate in different patients who develop new BPD.
As presented in this Special Issue, multiple interactive signaling pathways have been
implicated in the pathogenesis of new BPD from preclinical and clinical studies alike.
Hadchouel and coworkers provide an excellent overview of molecular mechanisms that alter
lung development in new BPD (Hadchouel A et al, 2014). Mechanisms that lead to
abnormal alveolarization and the development of a dysmorphic pulmonary circulation are
discussed in detail. Importantly, these authors cite essential elements that may link basic
studies with potential future therapeutic strategies. Strong evidence exists for critical roles of
several candidate factors, including those associated with lung matrix remodeling (such as
matrix metalloproteinases), growth factors that promote alveolarization (including platelet-
derived growth factor) and pro-angiogenic pathways (e.g., vascular endothelial growth
factor signaling) during normal lung development, and how altered expression or
manipulation of these factors in injury animal models (Figure 1C,D) can result in abnormal
lung structure that mimics human new BPD.
These concepts are further developed in the thorough review of alveolar-capillary
development and repair mechanisms in new BPD from Drs. Ahlfeld and Conway (Ahlfeld S
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and Conway SJ, 2014). These authors discuss links between histologic evidence of disrupted
alveolar-capillary structure in human infants with physiologic impairment of gas exchange.
Past work has shown a marked proliferation of vessels accompanying increased lung
parenchyma volume and surface area between 22–32 weeks gestation in the normal fetus,
which then continues to grow until term, albeit at a much slower rate (Thibeault DW et al,
2004). In marked contrast, patients dying with severe new BPD even late during infancy
generally have a dramatic reduction in septation and capillary volume, demonstrating
sustained abnormalities of distal lung architecture. They further highlight novel physiologic
assessments of diffusion capacity in human infants as providing physiologic proof of the
functional aspects of reduced surface area and discuss potential applications in animal
models. Although the new BPD has been characterized as an arrest of lung and vascular
growth, most of these observations were based on lung histology and evidence was lacking
that provided direct physiologic and functional data to support this finding. Recent work
from Tepper and colleagues has demonstrated the important finding of reduced lung surface
area in infants with new BPD by utilizing assessments of diffusion capacity (Balinotti JE et
al, 2010). Thus, established BPD is primarily characterized by reduced surface area and
heterogeneous lung units, in which regional variations in airway resistance and tissue
compliance lead to highly variable time constants throughout the lung.
The important roles of paracrine cellular and extracellular matrix interactions, especially
with regard to mesenchymal progenitors during alveolar development are the focus of Dr.
McGowan’s insightful review (McGowan S, 2014). A strong argument is made for the
essential role of an incredibly rich and dynamic mesenchymal environment during
development, which includes key interactions among diverse cells such as endothelium,
pericytes, fibroblasts and others, with neighboring epithelium. Clearly, the establishment of
normal lung structure is dependent upon complex cross-talk signaling mechanisms within
the developing mesenchyme as well as between mesenchyme and epithelium, and between
cells and their extracellular matrix.
Drs. Collins and Thebaud discuss the key roles of diverse endothelial and mesenchymal
progenitors in new BPD and potential therapeutic implications (Collins J and Thebaud B,
2014). Advances in stem cell biology have sparked interest in the reparative potential of
endothelial progenitor cells (EPCs). Preclinical studies suggest that lung and circulating
EPCs are decreased in experimental new BPD (Balasubramaniam V et al, 2010). Clinical
studies suggest that reduced EPCs in cord blood are strongly associated with risk for the
development of moderate to severe new BPD (Baker CD et al, 2012; Borghesi A et al,
2009). Mesenchymal stem cells (MSC) preserve lung development in rodent models of new
BPD (Aslam M et al, 2009; van Haaftern T et al, 2009). These effects do not require MSC
engraftment and are mediated through release of MSC-derived products [the “secretome”
(Abman SH and Matthay MA, 2009)], which may lead to novel interventions for BPD
prevention or treatment. However, much remains to be learned regarding how progenitor
cells contribute to normal lung development, whether decreased progenitor cell number or
impaired function actually contributes to new BPD and how to best apply such strategies to
human preterm infants at risk for (prevention) or with established (treatment) new BPD.
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In addition, two articles provide striking examples of highly specific critical signaling
pathways that are implicated in the pathobiology of new BPD. First, preclinical and clinical
studies over the years have strongly implicated lung inflammation and host immune
responses in the pathobiology of new BPD. For example, hyperoxia causes sustained
neutrophil-dominant inflammation in animal models and tracheal samples from infants who
develop new BPD (Ogden BE et al, 1984). Similarly, prenatal inflammation caused by
chorioamnionitis is generally linked to increased risk for new BPD in human infants
(Watterberg KL, et al, 1996) and causes BPD-like changes in lung histology in animal
models, even in the absence of postnatal injury (Tang JR et al, 2010). The nuclear factor K-
B (NFkB) family of transcription factors that are ubiquitously expressed throughout the lung
and have been shown to play critical roles in cell growth, survival and inflammation (Alvira
C, 2014). Based on past work by Dr. Alvira, NFkB signaling plays an essential role during
normal lung development yet further contributes to the pathogenesis of inflammation-
mediated disruption of lung growth. This “double-edged sword” nature of NFkB reflects its
complex biology and its ability to regulate a plethora of down-stream mediators. Insights
into the regulation of NFkB –related activities will likely lead to future interventions to
modulate outcomes of preterm infants at risk for new BPD.
Another example for the role of a specific factor and signaling pathway in the pathogenesis
of new BPD is represented by endothelial monocyte activating polypeptide II (EMAP II). As
reviewed by Drs. Lal and Schwartz, EMAP II highlights an exciting and growing story
around the important role for angiogenesis in the etiology of BPD (Lal CV and Schwarz M,
2014). Experimental studies have previously shown that early injury to the developing lung
can impair angiogenesis, which further contributes to decreased alveolarization and
simplification of distal lung airspaces (the “vascular hypothesis”) (Abman SH, 2001). For
example, VEGF, an endothelial cell-specific survival factor, stimulates angiogenesis and
protects against endothelial injury. Pharmacological and genetic VEGF inhibition during
perinatal development decreases alveolarization and pulmonary arterial density, (Jakkula M
et al, 2000; Thebaud B et al, 2005), features encountered in clinical BPD. Reduced VEGF
and VEGF receptor (VEGFR) have been reported in lungs of infants with fatal BPD (Bhatt
AJ et al, 2001; Lassus P et al, 2001). In this context, EMAP II has been shown to have anti-
angiogenic properties and is increased in the lungs of infants dying with severe BPD (Lal
CV and Schwarz M, 2014). This paper highlights how this novel pathway may become a
key target for therapeutic interventions to reduce the risk or severity of new BPD.
Finally, the clinical consequences of pulmonary vascular injury are discussed by Drs.
Ambalavanan and Mourani, who review the important problem of pulmonary hypertension
in BPD infants (Ambalavanan N and Mourani PM, 2014). Pulmonary hypertension is
strongly associated with poor survival in new BPD, either as a cause of death or as a
biomarker for more severe lung disease. This paper presents the “state-of-the-art” regarding
our current understanding of the epidemiology, pathophysiology and treatment of PH in
BPD. Abnormalities of the lung circulation in BPD are not only related to the presence or
absence of PH, but more broadly, pulmonary vascular disease after premature birth as
manifested by decreased vascular growth and structure also contributes to the abnormal
cardiopulmonary physiology of new BPD, including sustained impairment of surface area
for gas exchange.
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4. Spectrum of Respiratory Outcomes after Preterm Birth
Although the severity of new BPD is associated with a prolonged need for respiratory
support, oxygen therapy and prolonged NICU hospitalizations, major respiratory morbidities
extend throughout infancy, childhood and perhaps, adult life. Infants with new BPD are at
substantial risk for recurrent respiratory exacerbations, frequent hospitalizations with viral
infections, the need for asthma medications, exercise intolerance and related problems.
Although most infants show improvement with time, recent studies have shown persistent
abnormalities of lung function and structure in adult survivors of BPD. In fact, lung function
in some infants may worsen during infancy (Hoofhuis W et al, 2002). A study of 86
survivors of extreme preterm birth (<1,000 grams or gestational age ≤28 weeks) at 10 or 18
years of age found significantly higher high resolution computerized tomography (HRCT)
scores as well as more opacities and hypo-attenuated areas in subjects with a history of
moderate or severe new BPD than in those with a history of no or mild BPD (Auckland SM
et al, 2009). Similarly, abnormal HRCT scans with emphysematous changes were reported
in 19 subjects aged 17–33 years born at <1,500 grams with the diagnosis of moderate-to-
severe BPD, and these abnormal CT scans were correlated with abnormalities in pulmonary
function (Wong PM et al, 2008). Thus, there is evidence that severe BPD is associated with
life-long changes in pulmonary structure and function. However, more studies are needed to
accurately determine the long-term course of premature neonates with severe new BPD and
their relative contribution to the growing adult population.
Interestingly, there appears to be wide variability in late respiratory outcomes in preterm
cohorts. For example, a recent study of distal lung structure as assessed by hyperpolarized
helium magnetic resonance imaging (MRI) studies suggested that survivors of new BPD had
similar distal airspace structure as former preterm infants without a diagnosis of new BPD
and control term infants when studied during early adolescence (Narayanan M et al, 2013).
Although these studies did not provide serial measurements of subjects with BPD over time,
it appears that infants may have the ability to adapt and grow distal lung throughout
childhood, and that there remains substantial ability for late recovery. Insights into
mechanisms or mediators that may promote accelerated recovery and late compensatory
growth (so-called “resilience factors”) require further investigation.
5. Conclusions
BPD remains one of the most important causes of adverse health outcomes for infants born
prematurely. It is increasingly apparent that lung injury sustained in utero and shortly after
birth is a key determinant of later childhood and adult lung health and disease. Despite many
advances in perinatal care, few specific interventions have been proven as effective in
reducing the risk for or severity of new BPD. Insights into basic mechanisms of lung
development are essential for help in providing novel strategies for future interventions. The
social and economic impacts of impairment of lung health in subjects with BPD warrant a
renewed emphasis on research to prevent new BPD. Despite decades of promising findings,
strategies that effectively prevent new BPD are largely lacking. Continued translational
research, including “bench to bedside” approaches with animal models that best reflect the
evolving clinical epidemiology of new BPD, will likely be fruitful. In addition, high quality
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population-based studies are needed to better “endo-type” preterm infants at risk for new
BPD, and may help to identify epigenetic, genetic and proteomic biomarkers that predict
risk, provide insights into disease mechanisms or lead to better surrogate outcomes for
clinical trials. Finally, the need to develop better tools to improve physiologic and lung
imaging are vital for enhancing our understanding of disease course and outcomes and to
provide improved endpoints for better investigations to prevent new BPD and improve long-
term pulmonary outcomes.
As Guest Editors, we are thoroughly indebted to the authors for their expertise and informed
contributions, and hope that you will find this collection informative and stimulating.
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Figure 1. Histological presentation of new BPD
(A,B) Histology of a patient with fatal new BPD, demonstrating increased distal airspaces
with decreased sepatation and reduced alveolarization (A); as well as pulmonary vascular
wall thickness is present in small arteries (arrow in B), suggestive of pulmonary
hypertension. (C,D) Confocal images of postnatal day 7 mouse lungs exposed to either room
air (C) or 85% O2 hyperoxia (D) from birth onwards. Note that the hyperoxic lung exhibits
reduced alveolarization, exemplifying the alterations in distal airspace that mimics new
BPD, a chronic lung disease characterized by impaired gas exchange commonly found in
extremely premature infants exposed to mechanical ventilation and oxygen supplementation.
Nuclei are stained with DAPI (blue) and green signal is extracellular matrix
autofluorescence.
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